USD 0.73
(-1.35%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 14.41 Million USD | -43.98% |
2022 | 25.73 Million USD | -41.21% |
2021 | 43.77 Million USD | 235.14% |
2020 | 13.06 Million USD | -41.63% |
2019 | 22.37 Million USD | 503.28% |
2018 | 3.7 Million USD | 2.34% |
2017 | 3.62 Million USD | 29.09% |
2016 | 2.8 Million USD | -50.15% |
2015 | 5.63 Million USD | 525.15% |
2014 | 900.97 Thousand USD | 51.83% |
2013 | 593.42 Thousand USD | 60.57% |
2012 | 369.57 Thousand USD | -17.18% |
2011 | 446.22 Thousand USD | 169.01% |
2010 | 165.87 Thousand USD | -42.86% |
2009 | 290.29 Thousand USD | -63.21% |
2008 | 788.97 Thousand USD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 10.6 Million USD | -26.47% |
2024 Q2 | 10.58 Million USD | -0.13% |
2023 FY | 14.41 Million USD | -43.98% |
2023 Q4 | 14.41 Million USD | -20.64% |
2023 Q3 | 18.16 Million USD | -13.35% |
2023 Q2 | 20.96 Million USD | -16.34% |
2023 Q1 | 25.06 Million USD | -2.62% |
2022 FY | 25.73 Million USD | -41.21% |
2022 Q4 | 25.73 Million USD | -22.41% |
2022 Q3 | 33.16 Million USD | -9.12% |
2022 Q2 | 36.49 Million USD | -8.89% |
2022 Q1 | 40.05 Million USD | -8.48% |
2021 Q4 | 43.77 Million USD | -14.49% |
2021 FY | 43.77 Million USD | 235.14% |
2021 Q3 | 51.19 Million USD | -10.05% |
2021 Q1 | 39.65 Million USD | 203.62% |
2021 Q2 | 56.91 Million USD | 43.52% |
2020 Q1 | 25.04 Million USD | 11.95% |
2020 Q3 | 25.16 Million USD | -8.49% |
2020 Q4 | 13.06 Million USD | -48.09% |
2020 Q2 | 27.49 Million USD | 9.77% |
2020 FY | 13.06 Million USD | -41.63% |
2019 Q3 | 31.88 Million USD | -1.15% |
2019 Q2 | 32.25 Million USD | 534.0% |
2019 FY | 22.37 Million USD | 503.28% |
2019 Q1 | 5.08 Million USD | 37.15% |
2019 Q4 | 22.37 Million USD | -29.82% |
2018 Q2 | 4 Million USD | -33.31% |
2018 Q1 | 5.99 Million USD | 65.54% |
2018 Q3 | 5.41 Million USD | 35.36% |
2018 Q4 | 3.7 Million USD | -31.51% |
2018 FY | 3.7 Million USD | 2.34% |
2017 Q4 | 3.62 Million USD | 3.57% |
2017 FY | 3.62 Million USD | 29.09% |
2017 Q3 | 3.49 Million USD | -22.79% |
2017 Q2 | 4.53 Million USD | -17.09% |
2017 Q1 | 5.46 Million USD | 94.7% |
2016 FY | 2.8 Million USD | -50.15% |
2016 Q1 | 4.05 Million USD | -28.08% |
2016 Q4 | 2.8 Million USD | 46.45% |
2016 Q3 | 1.91 Million USD | -33.77% |
2016 Q2 | 2.89 Million USD | -28.55% |
2015 Q4 | 5.63 Million USD | -33.08% |
2015 Q3 | 8.41 Million USD | 1029.03% |
2015 Q2 | 745.45 Thousand USD | 2.83% |
2015 FY | 5.63 Million USD | 525.15% |
2015 Q1 | 724.91 Thousand USD | -19.54% |
2014 Q3 | 1.23 Million USD | 27.15% |
2014 Q1 | 997.48 Thousand USD | 68.09% |
2014 FY | 900.97 Thousand USD | 51.83% |
2014 Q2 | 972.77 Thousand USD | -2.48% |
2014 Q4 | 900.97 Thousand USD | -27.16% |
2013 Q4 | 593.42 Thousand USD | -6.79% |
2013 Q1 | 810.82 Thousand USD | 119.39% |
2013 Q2 | 443.57 Thousand USD | -45.29% |
2013 Q3 | 636.64 Thousand USD | 43.53% |
2013 FY | 593.42 Thousand USD | 60.57% |
2012 Q4 | 369.57 Thousand USD | -16.72% |
2012 Q2 | 375.13 Thousand USD | 10.1% |
2012 Q1 | 340.72 Thousand USD | -23.64% |
2012 FY | 369.57 Thousand USD | -17.18% |
2012 Q3 | 443.79 Thousand USD | 18.3% |
2011 Q2 | 250.56 Thousand USD | -48.32% |
2011 Q1 | 484.87 Thousand USD | 192.32% |
2011 FY | 446.22 Thousand USD | 169.01% |
2011 Q3 | 274.19 Thousand USD | 9.43% |
2011 Q4 | 446.22 Thousand USD | 62.74% |
2010 Q1 | 263.15 Thousand USD | -9.35% |
2010 Q3 | 179.89 Thousand USD | -11.95% |
2010 Q2 | 204.31 Thousand USD | -22.36% |
2010 Q4 | 165.87 Thousand USD | -7.8% |
2010 FY | 165.87 Thousand USD | -42.86% |
2009 FY | 290.29 Thousand USD | -63.21% |
2009 Q4 | 290.29 Thousand USD | -29.12% |
2009 Q3 | 409.53 Thousand USD | 0.0% |
2008 FY | 788.97 Thousand USD | 0.0% |
2008 Q4 | 788.97 Thousand USD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Akoya Biosciences, Inc. | 180.36 Million USD | 92.007% |
AngioDynamics, Inc. | 317.67 Million USD | 95.462% |
AtriCure, Inc. | 613.93 Million USD | 97.652% |
Avinger, Inc. | 13.77 Million USD | -4.7% |
Azenta, Inc. | 2.88 Billion USD | 99.5% |
BioLife Solutions, Inc. | 412.71 Million USD | 96.507% |
The Cooper Companies, Inc. | 11.65 Billion USD | 99.876% |
Daxor Corporation | 34.86 Million USD | 58.653% |
Ekso Bionics Holdings, Inc. | 28.91 Million USD | 50.144% |
Femasys Inc. | 27.75 Million USD | 48.057% |
GlucoTrack, Inc. | 4.9 Million USD | -193.93% |
Harvard Bioscience, Inc. | 137.36 Million USD | 89.504% |
Hologic, Inc. | 9.15 Billion USD | 99.843% |
ICU Medical, Inc. | 4.37 Billion USD | 99.671% |
Intuitive Surgical, Inc. | 15.44 Billion USD | 99.907% |
KORU Medical Systems, Inc. | 28.46 Million USD | 49.344% |
LeMaitre Vascular, Inc. | 346.77 Million USD | 95.843% |
Innovative Eyewear, Inc. | 6.21 Million USD | -131.835% |
Innovative Eyewear, Inc. | 6.21 Million USD | -131.835% |
Masimo Corporation | 3.04 Billion USD | 99.526% |
Microbot Medical Inc. | 8.32 Million USD | -73.139% |
Meihua International Medical Technologies Co., Ltd. | 171.91 Million USD | 91.614% |
Merit Medical Systems, Inc. | 2.32 Billion USD | 99.38% |
Nephros, Inc. | 11.86 Million USD | -21.552% |
NovoCure Limited | 1.14 Billion USD | 98.742% |
NEXGEL, Inc. | 9.95 Million USD | -44.824% |
NEXGEL, Inc. | 9.95 Million USD | -44.824% |
Singular Genomics Systems, Inc. | 265.46 Million USD | 94.569% |
OraSure Technologies, Inc. | 482.84 Million USD | 97.014% |
Pro-Dex, Inc. | 54.21 Million USD | 73.405% |
Pulse Biosciences, Inc. | 60.8 Million USD | 76.289% |
Precision Optics Corporation, Inc. | 16.91 Million USD | 14.754% |
QuidelOrtho Corporation | 8.56 Billion USD | 99.832% |
Repligen Corporation | 2.82 Billion USD | 99.49% |
Sanara MedTech Inc. | 73.87 Million USD | 80.483% |
STAAR Surgical Company | 488.69 Million USD | 97.05% |
Sharps Technology, Inc. | 11.78 Million USD | -22.291% |
Utah Medical Products, Inc. | 135.45 Million USD | 89.357% |
DENTSPLY SIRONA Inc. | 7.37 Billion USD | 99.804% |
Jin Medical International Ltd. | 32.9 Million USD | 56.183% |